PL3220937T3 - Mutanty pneumolizyny i sposoby ich stosowania - Google Patents

Mutanty pneumolizyny i sposoby ich stosowania

Info

Publication number
PL3220937T3
PL3220937T3 PL15861711.8T PL15861711T PL3220937T3 PL 3220937 T3 PL3220937 T3 PL 3220937T3 PL 15861711 T PL15861711 T PL 15861711T PL 3220937 T3 PL3220937 T3 PL 3220937T3
Authority
PL
Poland
Prior art keywords
methods
pneumolysin mutants
pneumolysin
mutants
Prior art date
Application number
PL15861711.8T
Other languages
English (en)
Inventor
Rodney K. Tweten
Original Assignee
The Board Of Regents Of The University Of Oklahoma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Regents Of The University Of Oklahoma filed Critical The Board Of Regents Of The University Of Oklahoma
Publication of PL3220937T3 publication Critical patent/PL3220937T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
PL15861711.8T 2014-11-21 2015-11-20 Mutanty pneumolizyny i sposoby ich stosowania PL3220937T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462082848P 2014-11-21 2014-11-21
PCT/US2015/061859 WO2016081839A1 (en) 2014-11-21 2015-11-20 Pneumolysin mutants and methods of use thereof

Publications (1)

Publication Number Publication Date
PL3220937T3 true PL3220937T3 (pl) 2025-01-27

Family

ID=56014598

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15861711.8T PL3220937T3 (pl) 2014-11-21 2015-11-20 Mutanty pneumolizyny i sposoby ich stosowania

Country Status (21)

Country Link
US (1) US10562941B2 (pl)
EP (2) EP3220937B1 (pl)
JP (1) JP6734274B2 (pl)
KR (1) KR102304828B1 (pl)
CN (1) CN107106635B (pl)
AU (1) AU2015349787B2 (pl)
CA (1) CA2968398A1 (pl)
DK (1) DK3220937T3 (pl)
ES (1) ES2993430T3 (pl)
FI (1) FI3220937T3 (pl)
HR (1) HRP20241627T1 (pl)
HU (1) HUE069200T2 (pl)
LT (1) LT3220937T (pl)
MX (1) MX381872B (pl)
PL (1) PL3220937T3 (pl)
PT (1) PT3220937T (pl)
RS (1) RS66221B1 (pl)
SI (1) SI3220937T1 (pl)
SM (1) SMT202400482T1 (pl)
WO (1) WO2016081839A1 (pl)
ZA (1) ZA201703881B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012134975A1 (en) 2011-03-28 2012-10-04 St. Jude Children's Research Hospital Methods and compositions employing immunogenic fusion proteins
EP3562838A2 (en) 2016-12-28 2019-11-06 Henriques Normark, Birgitta Microparticles from streptococcus pneumoniae as vaccine antigens
CN110967482B (zh) * 2018-09-30 2023-04-07 重庆市畜牧科学院 一种山羊化脓隐秘杆菌感染检测试剂盒及其检测方法
CN113264999B (zh) * 2021-04-29 2023-02-28 星济生物(苏州)有限公司 中和肺炎链球菌溶血素蛋白的抗原结合蛋白及其用途
IL311239A (en) * 2021-09-09 2024-05-01 Affinivax Inc Multivalent pneumococcal vaccines
AU2022391752A1 (en) 2021-11-18 2024-06-13 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
CN115927420A (zh) * 2022-05-27 2023-04-07 贵州省畜牧兽医研究所 一种溶血素重组表达及间接elisa检测方法及应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686102A (en) 1984-04-12 1987-08-11 American Cyanamid Company Multivalent pneumococcal vaccine and preparation thereof
HUT58804A (en) 1988-12-16 1992-03-30 James Cleland Paton Process for producing pneumolysine mutants and pneumococcus vaccines
US6716432B1 (en) 1988-12-16 2004-04-06 James Cleland Paton Pneumolysin mutants and pneumococcal vaccines made therefrom
US5854416A (en) 1991-11-14 1998-12-29 The United States Of America As Represented By The Department Of Health And Human Services Streptococcus pneumoniae 37-KDA surface adhesin a protein and nucleic acids coding therefor
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
CA2221480A1 (en) 1995-06-07 1996-12-19 The Regents Of The University Of Minnesota Mutants of streptococcal toxin a and methods of use
KR100619350B1 (ko) 1997-07-21 2006-09-05 박스터 헬쓰케어 에스.에이. 변형 면역성 뉴멀리신 백신조성물
US6224880B1 (en) 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
US6903184B1 (en) 1998-03-02 2005-06-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Multiple antigenic peptides immunogenic against Streptococcus pneumonia
EP1098980B1 (en) 1998-07-22 2014-09-03 Stichting Dienst Landbouwkundig Onderzoek Streptococcus suis vaccines and diagnostic tests
US6582706B1 (en) 1998-12-21 2003-06-24 Medimmune, Inc. Vaccine compositions comprising Streptococcus pneumoniae polypeptides having selected structural MOTIFS
US6887480B1 (en) 1999-06-10 2005-05-03 Medimmune, Inc. Streptococcus pneumoniae proteins and vaccines
US7262024B2 (en) 2001-12-20 2007-08-28 Id Biomedical Corporation Streptococcus antigens
JP2006506989A (ja) 2002-11-07 2006-03-02 シナジー アメリカ,インコーポレイテッド 肺炎球菌感染を治療または予防するための組成物および方法
WO2005076696A2 (en) 2004-02-13 2005-08-25 Sanofi Pasteur Limited Pneumolysin derivatives
GB0410220D0 (en) * 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
WO2005108419A1 (en) 2004-05-07 2005-11-17 Lea-Ann Kirkham Mutant cholesterol-binding cytolysin proteins
US9370557B2 (en) 2006-06-15 2016-06-21 The University Court Of The University Of Glasgow Adjuvant compounds
EP2386567B1 (en) * 2007-04-13 2014-10-29 The Board Of Regents Of The University Of Oklahoma Mutants of cholesterol-dependent cytolysins and uses thereof
CA2748149C (en) 2008-12-24 2018-03-06 Netherlands Vaccine Institute Modified steptococcus pneumonia pneumolysin (ply) polypeptides
WO2011075822A1 (en) * 2009-12-22 2011-06-30 Sanofi Pasteur Limited Immunogenic compositions and related methods
CL2010001216A1 (es) * 2010-11-08 2011-01-28 New Tech Copper S P A Sistema para confinar el espacio sobre el electrolito en una celda de electro obtencion y evacuar los aerosoles generados, que comprende un confinador insertado en cada anodo, con un par de proyecciones flexibles y un par de perfiles en angulo, y ductos longitudinales con perforaciones sobre el nivel del electrolito.
WO2012134975A1 (en) 2011-03-28 2012-10-04 St. Jude Children's Research Hospital Methods and compositions employing immunogenic fusion proteins
JP6397805B2 (ja) 2015-08-28 2018-09-26 東芝メモリ株式会社 半導体製造装置およびその運転方法

Also Published As

Publication number Publication date
RS66221B1 (sr) 2024-12-31
DK3220937T3 (da) 2024-12-02
JP6734274B2 (ja) 2020-08-05
CN107106635A (zh) 2017-08-29
JP2017536124A (ja) 2017-12-07
EP4501949A2 (en) 2025-02-05
WO2016081839A1 (en) 2016-05-26
BR112017010696A2 (pt) 2017-12-26
MX381872B (es) 2025-03-13
EP4501949A3 (en) 2025-04-30
LT3220937T (lt) 2024-12-27
KR102304828B1 (ko) 2021-09-27
FI3220937T3 (fi) 2024-11-29
AU2015349787A1 (en) 2017-06-22
HRP20241627T1 (hr) 2025-02-14
HUE069200T2 (hu) 2025-02-28
EP3220937A1 (en) 2017-09-27
EP3220937B1 (en) 2024-09-04
US10562941B2 (en) 2020-02-18
CA2968398A1 (en) 2016-05-26
SMT202400482T1 (it) 2025-01-14
SI3220937T1 (sl) 2025-03-31
US20180312552A1 (en) 2018-11-01
AU2015349787B2 (en) 2021-07-29
PT3220937T (pt) 2024-11-18
ZA201703881B (en) 2021-10-27
ES2993430T3 (en) 2024-12-30
EP3220937A4 (en) 2018-05-30
CN107106635B (zh) 2021-10-08
MX2017006625A (es) 2018-01-15
KR20170083635A (ko) 2017-07-18

Similar Documents

Publication Publication Date Title
IL286316A (en) New micro-dystrophins and related method of use
IL250415B (en) Antibodies against pd-l and methods of using them
IL258768A (en) Compounds interacting with glycans and methods of use
IL251868A0 (en) Anti-tim3 antibodies and methods of use
IL251970A0 (en) Anti-cd79b antibodies and methods of use
PL3548033T3 (pl) Związki i sposoby ich stosowania
HUE061672T2 (hu) Glikán-interakcióban lévõ vegyületek és felhasználási módszerek
IL246736A0 (en) Anti-jagged1 antibodies and methods of use
PT3089971T (pt) Compostos e métodos de utilização
IL247754A0 (en) Antibodies against mcam and related methods of use
IL251165A0 (en) Anti-il-1beta antibodies and methods of their use
IL253234B (en) Methods for transdifferentiation and methods to use them
GB201417048D0 (en) Occupancy-control device and methods of use
IL251286A0 (en) Anti-pdgf-b antibodies and methods of use
ZA201703881B (en) Pneumolysin mutants and methods of use thereof
SG11201605915WA (en) Furo-3-carboxamide derivatives and methods of use
ZA201606450B (en) Compounds and their methods of use
IL247448A0 (en) Peptides and methods of use
GB201403697D0 (en) Compounds and methods of use
GB201416797D0 (en) Contianer and method of use thereof